This workshop convened a wide array of stakeholders, including representation from patients and consumer advocacy groups, oncology and other professional groups, federal research and regulatory agencies, public and private payors, molecular diagnostics developers, pharmaceutical companies, clinical laboratories, researchers, and organizations that develop clinical practice guidelines.